Accelerated Diabetic Nephropathy in Mice Lacking the Peroxisome Proliferator–Activated Receptor α
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator–activated receptor (PPAR)α, a member of the ligand-activated nuclear receptor superfamily, plays an important role in lipid metabolism and glucose homeostasis and is highly expressed in the kidney. The present studies were aimed at determining the role of PPARα in the pathogenesis of diabetic nephropathy using PPARα-knockout mice and cultured murine mesangial cells. Diabetes was induced using a low-dose streptozotocin protocol in 8-week-old male 129 SvJ PPARα-knockout and wild-type mice. Diabetic PPARα-knockout and wild-type mice developed elevated fasting blood glucose (P < 0.001) and HbA1c levels (P < 0.001). Renal functional and histopathological changes in diabetic and nondiabetic PPARα-knockout and wild-type mice were evaluated after 16 weeks of hyperglycemia. PPARα immunostaining of the cortical tubules of diabetic wild-type mice was elevated by hyperglycemia. In diabetic PPARα-knockout mice, renal disease with accompanying albuminuria, glomerular sclerosis, and mesangial area expansion was more severe than in diabetic wild-type mice (P < 0.05) and was accompanied by increased levels of serum free fatty acids and triglycerides (P < 0.01). Furthermore, they exhibited increased renal immunostaining for type IV collagen and osteopontin, which was associated with increased macrophage infiltration and glomerular apoptosis. There were no significant differences in these indexes of renal disease between nondiabetic PPARα-knockout and wild-type mice and diabetic PPARα wild-type mice. In vitro studies demonstrated that high glucose levels markedly increased the expression of type IV collagen, transforming growth factor-β1, and the number of leukocytes adherent to cultured mesangial cells. Adherence of leukocytes was inhibited by the PPARα agonist fenofibrate. Taken together, PPARα deficiency appears to aggravate the severity of diabetic nephropathy through an increase in extracellular matrix formation, inflammation, and circulating free fatty acid and triglyceride concentrations. PPARα agonists may serve as useful therapeutic agents for type 1 diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519 · cited 1×
“Peroxisome proliferator–activated receptor (PPAR) is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors and plays an important role in lipid metabolism (1).”
BackgroundPeroxisome proliferator–activated receptor α mediates the adaptive response to fasting
Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., & Wahli, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6223 · Cited by 1,649
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345 · cited 1×
“Because PPAR enhances the activity of the -oxidation pathway, the consequent degradation of arachidonic acid and leukotrienes directly results in the termination of inflammation (24).”
BackgroundSchoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Finck, B. N., Han, X., Courtois, M., Aimond, F., Nerbonne, J. M., Kovacs, A., Gross, R. W., & Kelly, D. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336724100 · Cited by 501
Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117717 · Cited by 410 · cited 1×
“It is well known that PPAR agonists lower triglyceride levels by increasing lipoprotein lipase gene expression via a PPAR response element (PPRE) in the LPL promoter (18) and decreasing apo C-III levels (19), thus resulting in an enhanced lipolytic activity.”
BackgroundDjouadi, F., Weinheimer, C. J., Saffitz, J. E., Pitchford, C., Bastin, J., Gonzalez, F. J., & Kelly, D. P. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3949 · Cited by 410
Renal injury in apolipoprotein E-deficient mice
Wen, M., Segerer, S., Dantas, M., Brown, P. A., Hudkins, K. L., Goodpaster, T., Kirk, E., LeBoeuf, R. C., & Alpers, C. E. (2002) · Laboratory Investigation · doi:10.1097/01.lab.0000022222.03120.d4 · Cited by 104 · cited 1×
“Mesangial matrix area and glomerular tuft area were quantified for each glomerular cross section as previously reported (13).”
Method
Cited by
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
“For example, thiazolidinediones, which are peroxisome proliferator activated receptors (PPAR ␥ agonists) (14), have shown beneficial effects on complications , which are independent of their glucose lowering action (449).”
BackgroundInfluentialInflammation and the pathogenesis of diabetic nephropathy
Wada, J., & Makino, H. (2013) · Clinical Science · doi:10.1042/cs20120198 · Cited by 775
Mitochondrial Damage and Activation of the STING Pathway Lead to Renal Inflammation and Fibrosis
Chung, K. W., Dhillon, P., Huang, S., Sheng, X., Shrestha, R., Qiu, C., Kaufman, B. A., Park, J., Pei, L., Baur, J., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.003 · Cited by 651
Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease
Mitrofanova, A., Merscher, S., & Fornoni, A. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00741-w · Cited by 356
Proctor, G., Jiang, T., Iwahashi, M., Wang, Z., Li, J., & Levi, M. (2006) · Diabetes · doi:10.2337/db05-0603 · Cited by 303
Metadata
- Authors
- Park, C. W., Kim, H. W., Ko, S. H., Chung, H. W., Lim, S. W., Yang, C. W., Chang, Y. S., Sugawara, A., Guan, Y., & Breyer, M. D.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2006-04-01
- Volume
- 55
- Issue
- 4
- Pages
- 885-893
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2099262759
- Cited by
- 144
- References
- 8
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Accelerated Diabetic Nephropathy in Mice Lacking the Peroxisome Proliferator–Activated Receptor α. https://app.cochat.ai/papers/10.2337/diabetes.55.04.06.db05-1329
- The paper
- Park, C. W., Kim, H. W., Ko, S. H., Chung, H. W., Lim, S. W., Yang, C. W., Chang, Y. S., Sugawara, A., Guan, Y., & Breyer, M. D. (2006). Accelerated Diabetic Nephropathy in Mice Lacking the Peroxisome Proliferator–Activated Receptor α. Diabetes. https://doi.org/10.2337/diabetes.55.04.06.db05-1329
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.